Conavi Medical Announces New Grant of Stock Options

Core Points - Conavi Medical Corp. has approved the grant of 5,849,098 stock options to its directors, officers, employees, and consultants under its Omnibus Equity Incentive Plan [1] - The stock options are exercisable at a price of $0.39 CAD per share for a period of 10 years from the grant date [1] - The allocation of stock options includes 1,930,172 options to independent directors and 3,581,216 options to officers, with the remainder going to other employees and consultants [2][3] Allocation Details - Independent directors received the following stock options: Anthony Giovinazzo (341,624), Cathy Steiner (341,624), Robert Mitchell (330,807), Susan Allen (358,242), and Aaron Davidson (557,875) [2] - Officers received the following stock options: Travis More (298,413), Amandeep Thind (266,863), Sumeet Dham (393,924), Stefano Picone (425,000), and Thomas Looby (2,197,646) [3] Audit Committee Changes - Minor changes were made to the composition of the Audit Committee, with Aaron Davidson stepping down and Susan Allen, Cathy Steiner, and Robert Mitchell continuing to serve [4] Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [5] - The Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous imaging of coronary arteries [5] - The system has received regulatory approvals from the U.S. FDA, Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare [5]